SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as investors focus on its role in building decentralized AI infrastructure, with significant community excitement surrounding its potential as a long-term asset akin to early-stage growth plays. Discussions are heavily focused on the project's subnet ecosystem, institutional interest, and the strategy of staking as a means to accumulate value despite broader market volatility.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is attracting significant attention as community members analyze its resilience amidst geopolitical tensions and supply chain complexities while weighing the impact of its major Small Modular Reactor (SMR) contracts and defense partnerships. Investors are actively discussing the company's long-term transformation, focusing on whether current volatility provides an optimal entry point or signals broader headwinds for its commercial aerospace engine business.

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX's Nasdaq debut has triggered intense debate, with the stock drawing record trading volumes and massive institutional inflows despite significant concerns over its lack of profitability and sky-high valuation. While bullish investors view the company as a transformative leader in space and AI infrastructure, the community remains divided as traders focus on the upcoming options chain launch and the technical implications of its massive market capitalization.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP CRYPTO is experiencing significant volatility and intense community debate as investors react to ongoing concerns about the project's long-term utility and its association with political figures. While some traders are attempting to capitalize on short-term price fluctuations, the broader community is deeply polarized, with many users openly questioning the project's transparency and citing sharp declines from historical highs as evidence of potential risks.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF (VTI) remains a primary focal point for investors as the community debates broader market volatility linked to ongoing Middle East conflicts and shifting economic sentiment under current federal fiscal policies. Sentiment remains divided, with retail investors increasingly focused on balancing long-term dollar-cost averaging strategies against concerns regarding inflationary pressures and the potential for a sustained market pullback.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors react to a significant patent extension securing exclusivity through 2041 and subsequent analyst price target upgrades, fueling a surge in volume and stock price to multi-year highs. The community is actively debating the implications of this news for a potential buyout while closely monitoring the status of European regulatory milestones and management's ongoing clinical development strategy.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending due to the community's relentless focus on organic growth and the proliferation of diverse, community-led initiatives like consumer products and IRL brand integration. Supporters are actively discussing their conviction in these projects, emphasizing a 'work-not-gamble' culture while steadily accumulating tokens to build long-term value.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is experiencing significant volatility as investors weigh disappointing monthly sales data against anticipated long-term milestones like J-code reimbursement and potential European market expansion. The community remains deeply divided, with many shareholders dismissing the price drop as algorithmic manipulation and short-term weakness while expressing frustration over management's lack of transparency regarding recent executive departures.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is capturing attention as traders monitor a potential breakout from long-term consolidation, with the community actively debating whether recent ecosystem expansions and IoT narratives can drive a shift in momentum. While bullish supporters are focused on potential institutional adoption and increased trading volume, skeptics remain vocal, highlighting ongoing concerns about tokenomics, historical price performance, and the emergence of competing projects within the broader ecosystem.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are actively weighing the impact of heightened geopolitical instability in the Middle East and cooling economic data against the potential for near-term interest rate shifts. The community remains divided, with intense debate centered on the reliability of official economic reports versus the market's continued rotation out of mega-cap tech into more defensive or value-oriented sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.read more...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Misses Expectations By $3.04 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $16.00 by Analysts at Needham & Company LLC

Needham & Company LLC dropped their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Wednesday...

BioCryst Pharmaceuticals Q1 Earnings Call Highlights

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described as a strong start to 2026, driven by continued growth of hereditary angioedema (HAE) therapy ORLADEYO and progress across its development pipeline, while also flagging a manufacturing issue that will delay initial fulfillment...

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -150.00% and +0.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday

BioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock...

Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Phocas Financial Corp. acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The...

SG Americas Securities LLC Sells 102,210 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

SG Americas Securities LLC lessened its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 44.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC...

Aberdeen Group plc Buys Shares of 913,593 BioCryst Pharmaceuticals, Inc. $BCRX

Aberdeen Group plc acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Current Price	$8.70
Prev Close	$8.50
Open	$8.47
Dividend Yield	0.00%
50-Day Moving Average	$8.95
Beta	0.95
Avg. Volume	5.09M
PE Ratio	-4.90

52-Week High	$10.47
52-Week Low	$6.00
Market Capitalization	$2.16B
EPS (Annual)	$1.21
Price to Book	-3.99
Revenue Per Employee	$2.01M

BCRXBiocryst Pharmaceuticals Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News